NACC2 (nucleus accumbens-associated protein 2) functions as a transcriptional repressor that recruits the NuRD chr9 remodeling complex to regulate gene expression, particularly MDM2 transcription, thereby stabilizing p53 1. The protein contains a BTB domain that enables protein multimerization and clustering into nuclear foci, a property shared with other transcription factors 1. In disease contexts, NACC2 dysregulation has emerged as clinically significant across multiple pathologies. LINE-1 retrotransposon insertion into the NACC2 locus disrupts the HDM2/TP53/RB regulatory axis in lung cancer, reducing NACC2 expression and promoting oncogenic signaling 2. NACC2-NTRK2 fusion proteins drive pediatric brain tumors through BTB domain-mediated multimerization, activating aberrant tyrosine kinase signaling 3, and NTRK inhibitor larotrectinib shows clinical benefit in NACC2-NTRK2 fusion-positive pediatric cancers 4. In Alzheimer's disease, miR-132-dependent NACC2 regulation modulates adult hippocampal neurogenesis and neuroinflammatory responses 5. Additionally, miR-199a-3p-mediated NACC2 downregulation promotes cardiomyocyte recovery following myocardial infarction 6, and elevated plasma NACC2 serves as a potential biomarker for vascular endothelial cell injury from air pollution exposure 7. These findings establish NACC2 as a multifunctional transcriptional regulator with therapeutic and diagnostic implications across neurodegenerative, oncologic, and cardiovascular disease.